Advancing patient care with clinical validation: SEALANT safety results

Stent assisted coiling is used widely wherever aneurysms are treated…but where’s the evidence to support it? That’s the impetus behind the SEALANT Study designed to answer key questions about the safety and efficacy of stent assisted coiling.

To learn more about this multicenter European study, with special emphasis on Microvention’s LVIS® Evo™ and the HydroCoil® Embolic system, we join Professor Markus Möhlenbruch (Germany) and Doctor Jonathan Downer (UK) during the recent LINNC Paris 2024 who reveal the most recent data that emerged from SEALANT.

What have they found so far?
That looking at the over 200 patients in the intention to treat population participating in this study, the discharge safety analysis shows low rates of periprocedural morbidity and no mortality, with few complications having clinical impact (less than 1%).

Besides learning about the broad inclusion criteria which did not limit the size of the aneurysms treated, you will discover which of the treatment techniques were used; whether stents were deployed before the coiling procedure, whether a jailing technique was employed, or if coiling was done first, with or without a balloon.

And while we’ll have to wait for next year’s LINNC Course and SEALANT’s 1-year follow-up data to confirm occlusion rates and longer-term procedural success, join us now and find out why the use of the LVIS® Evo™ and the HydroCoil® Embolic system is very promising!

Sponsored by MicroVention